Research programme: kinase inhibitors - Pierre Fabre/SGX Pharmaceuticals

Drug Profile

Research programme: kinase inhibitors - Pierre Fabre/SGX Pharmaceuticals

Alternative Names: Kinase inhibitors - SGX/UroGene

Latest Information Update: 10 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SGX Pharmaceuticals; UroGene
  • Class Small molecules
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bladder cancer

Most Recent Events

  • 31 Aug 2005 Structural GenomiX is now called SGX Pharmaceuticals
  • 23 Dec 2003 Preclinical trials in Bladder cancer in France (unspecified)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top